Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric P Krenning

Showing results (61-70 of 173) with videos related to

Pageof 18
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 29, 2011
Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotateSaima Khan, Eric P Krenning, Martijn van Essen, et al.
Nuclear Medicine and Biology|August 25, 2015
In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligandsAikaterini Kaloudi, Berthold A Nock, Emmanouil Lymperis, et al.
Seminars in Nuclear Medicine|June 1, 2011
(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectivesWouter A P Breeman, Erik de Blois, Ho Sze Chan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 5, 2006
Anticancer activity of targeted proapoptotic peptidesAstrid Capello, Eric P Krenning, Bert F Bernard, et al.
Best Practice & Research. Clinical Gastroenterology|September 27, 2005
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapyJaap J M Teunissen, Dik J Kwekkeboom, Marion de Jong, et al.
Nuclear Medicine Communications|March 20, 2008
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotideRaffaella Barone, Stéphan Walrand, Mark Konijnenberg, et al.
Purinergic Signalling|November 10, 2021
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signallingDjo Hasan, Atsuko Shono, Coenraad K van Kalken, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2013
Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotateEsther I van Vliet, Eric P Krenning, Jaap J Teunissen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 19, 2005
Radiolabelling DOTA-peptides with 68GaWouter A P Breeman, Marion de Jong, Erik de Blois, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitroAstrid Capello, Eric P Krenning, Wout A P Breeman, et al.
Pageof 18

Showing results (61-70 of 173) with videos related to

Sort By:
Pageof 18
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 29, 2011
Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotateSaima Khan, Eric P Krenning, Martijn van Essen, et al.
Nuclear Medicine and Biology|August 25, 2015
In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligandsAikaterini Kaloudi, Berthold A Nock, Emmanouil Lymperis, et al.
Seminars in Nuclear Medicine|June 1, 2011
(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectivesWouter A P Breeman, Erik de Blois, Ho Sze Chan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 5, 2006
Anticancer activity of targeted proapoptotic peptidesAstrid Capello, Eric P Krenning, Bert F Bernard, et al.
Best Practice & Research. Clinical Gastroenterology|September 27, 2005
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapyJaap J M Teunissen, Dik J Kwekkeboom, Marion de Jong, et al.
Nuclear Medicine Communications|March 20, 2008
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotideRaffaella Barone, Stéphan Walrand, Mark Konijnenberg, et al.
Purinergic Signalling|November 10, 2021
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signallingDjo Hasan, Atsuko Shono, Coenraad K van Kalken, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2013
Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotateEsther I van Vliet, Eric P Krenning, Jaap J Teunissen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 19, 2005
Radiolabelling DOTA-peptides with 68GaWouter A P Breeman, Marion de Jong, Erik de Blois, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitroAstrid Capello, Eric P Krenning, Wout A P Breeman, et al.
Pageof 18